<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8" />
    <title>Elisence – Phase 4 · Stability, Integrity & Comparative Intelligence</title>
    <meta name="viewport" content="width=device-width, initial-scale=1" />
    <meta
        name="description"
        content="Elisence Phase 4 – Stability, Integrity & Comparative Intelligence Layer. WORM ledger, FHIR interoperability, provenance, AKAC and global medical intelligence."
    />

    <!-- Elisa chat widget script (مثل index و phase2) -->
    <script defer src="elisa-chat.js"></script>

    <style>
        * {
            box-sizing: border-box;
            margin: 0;
            padding: 0;
        }

        body {
            min-height: 100vh;
            font-family: system-ui, -apple-system, BlinkMacSystemFont, "Segoe UI", sans-serif;
            background: radial-gradient(circle at top, #04101f 0%, #02040a 45%, #000000 100%);
            color: #ffffff;
            overflow-x: hidden;
            line-height: 1.6;
        }

        /* نقطه و برچسب بالا */
        .top-dot {
            position: fixed;
            left: 18px;
            top: 18px;
            width: 14px;
            height: 14px;
            border-radius: 50%;
            background: radial-gradient(circle, #34c8ff, #0065ff 65%, #000c28 100%);
            box-shadow: 0 0 18px rgba(0, 170, 255, 0.9);
            z-index: 20;
        }

        .top-dot-label {
            position: fixed;
            left: 40px;
            top: 16px;
            font-size: 14px;
            letter-spacing: 0.22em;
            text-transform: uppercase;
            color: #a9d4ff;
            z-index: 20;
        }

        /* منوی عمودی سمت راست (هم‌استایل index/phase2) */
        .side-nav {
            position: fixed;
            right: 32px;
            top: 50%;
            transform: translateY(-50%);
            display: flex;
            flex-direction: column;
            gap: 12px;
            z-index: 999;
        }

        .nav-btn {
            display: block;
            padding: 13px 38px;
            border-radius: 999px;
            text-decoration: none;
            font-size: 14px;
            letter-spacing: 0.14em;
            text-transform: uppercase;
            color: #e3f2ff;
            background: radial-gradient(circle at top, rgba(0, 130, 255, 0.45), rgba(0, 10, 35, 0.97));
            border: 1px solid rgba(90, 185, 255, 0.9);
            box-shadow:
                0 0 16px rgba(0, 130, 255, 0.95),
                0 0 34px rgba(0, 40, 120, 0.95);
            transition: transform 0.2s ease, box-shadow 0.2s ease, background 0.2s ease, padding 0.2s ease;
        }

        .nav-btn:hover {
            transform: translateX(-4px);
            padding-right: 44px;
            box-shadow:
                0 0 22px rgba(0, 190, 255, 1),
                0 0 46px rgba(0, 80, 200, 1);
            background: radial-gradient(circle at top, rgba(0, 170, 255, 0.7), rgba(0, 25, 80, 1));
        }

        .nav-btn:active {
            transform: translateX(-2px) scale(0.99);
        }

        /* شِل اصلی صفحه */
        .page-wrapper {
            min-height: 100vh;
            padding: 80px 40px 80px 40px;
            display: flex;
            justify-content: center;
        }

        .content-shell {
            width: 100%;
            max-width: 1100px;
            margin-right: 190px; /* جا برای منوی راست روی دسکتاپ */
        }

        /* کارت هیرو بالا (مثل فاز ۲) */
        .hero-card {
            border-radius: 26px;
            padding: 34px 34px 30px 34px;
            background: radial-gradient(circle at top, rgba(0, 156, 255, 0.32), rgba(0, 12, 40, 0.96));
            box-shadow:
                0 0 45px rgba(0, 170, 255, 0.85),
                0 0 120px rgba(0, 80, 200, 0.65);
            border: 1px solid rgba(70, 190, 255, 0.6);
            margin-bottom: 26px;
        }

        .hero-layout {
            display: grid;
            grid-template-columns: minmax(0, 1.1fr) minmax(0, 1.9fr);
            gap: 26px;
            align-items: center;
        }

        .hero-logo-container {
            width: 100%;
            max-width: 430px;
            margin: 0 auto;
        }

        .main-hero-logo {
            width: 100%;
            height: auto;
            border-radius: 18px;
            animation: breathingGlow 6s infinite ease-in-out;
            filter: drop-shadow(0 0 20px rgba(0, 160, 255, 0.6));
        }

        @keyframes breathingGlow {
            0%, 100% {
                filter: drop-shadow(0 0 25px rgba(0, 160, 255, 0.5)) brightness(1);
                transform: scale(1);
            }
            50% {
                filter: drop-shadow(0 0 50px rgba(0, 200, 255, 0.9)) brightness(1.15);
                transform: scale(1.015);
            }
        }

        .phase-label {
            font-size: 11px;
            letter-spacing: 0.18em;
            text-transform: uppercase;
            color: #a5d7ff;
            margin-bottom: 6px;
        }

        .hero-title {
            font-size: 26px;
            letter-spacing: 0.20em;
            text-transform: uppercase;
            font-weight: 700;
            margin-bottom: 6px;
        }

        .hero-tagline {
            font-size: 13px;
            color: #d4e8ff;
            margin-bottom: 10px;
        }

        .hero-body {
            font-size: 13px;
            color: #dbefff;
        }

        .hero-footnote {
            margin-top: 16px;
            font-size: 11px;
            letter-spacing: 0.14em;
            text-transform: uppercase;
            color: #7fb5ff;
        }

        /* کارت‌های پایین (grid مثل دو جدول فاز۲، ولی بیشتر کارت) */
        .card-grid {
            margin-top: 10px;
            display: grid;
            grid-template-columns: repeat(2, minmax(0, 1fr));
            gap: 18px;
        }

        @media (max-width: 900px) {
            .page-wrapper {
                padding: 80px 18px 110px 18px;
            }

            .content-shell {
                margin-right: 0;
            }

            .hero-layout {
                grid-template-columns: minmax(0, 1fr);
            }

            .card-grid {
                grid-template-columns: minmax(0, 1fr);
            }

            .side-nav {
                position: fixed;
                right: 50%;
                top: auto;
                bottom: 18px;
                transform: translateX(50%);
                flex-direction: row;
                flex-wrap: wrap;
                justify-content: center;
                gap: 8px;
            }

            .nav-btn {
                padding: 9px 20px;
                font-size: 11px;
                letter-spacing: 0.11em;
            }
        }

        .info-card {
            border-radius: 20px;
            padding: 18px 18px 18px 18px;
            background: radial-gradient(circle at top, rgba(0, 120, 255, 0.40), rgba(0, 15, 40, 0.96));
            border: 1px solid rgba(90, 185, 255, 0.85);
            box-shadow:
                0 0 22px rgba(0, 140, 255, 0.9),
                0 0 40px rgba(0, 40, 120, 0.9);
        }

        .info-title {
            font-size: 13px;
            letter-spacing: 0.16em;
            text-transform: uppercase;
            color: #a9d4ff;
            margin-bottom: 8px;
        }

        .info-subtitle {
            font-size: 12px;
            color: #93c5fd;
            margin-bottom: 6px;
        }

        .info-body {
            font-size: 12.5px;
            color: #dbefff;
        }

        .info-body p {
            margin-bottom: 6px;
        }

        .info-body ul {
            margin: 4px 0 6px 18px;
            padding-left: 0;
        }

        .info-body li {
            margin-bottom: 4px;
        }

        .highlight {
            font-weight: 600;
            color: #7dd3fc;
        }
    </style>
</head>
<body>

    <div class="top-dot"></div>
    <div class="top-dot-label">ELISENCE</div>

    <!-- منوی عمودی سمت راست -->
    <nav class="side-nav">
        <a href="index.html"        class="nav-btn">Home</a>
        <a href="index.html#phases" class="nav-btn">Phases</a>
        <a href="about.html"        class="nav-btn">About</a>
        <a href="story.html"        class="nav-btn">Story</a>
        <a href="video.html"        class="nav-btn">Videos</a>
        <a href="contact.html"      class="nav-btn">Contact</a>
    </nav>

    <div class="page-wrapper">
        <div class="content-shell">

            <!-- هیرو فاز ۴ -->
            <section class="hero-card">
                <div class="hero-layout">

                    <!-- لوگو -->
                    <div class="hero-logo-container">
                        <img
                            src="elisence.png"
                            alt="Elisence – Global Digital Health & Humanity Platform"
                            class="main-hero-logo"
                        />
                    </div>

                    <!-- متن خلاصه -->
                    <div>
                        <div class="phase-label">Phase 4 · Stability, Integrity & Comparative Intelligence Layer</div>
                        <div class="hero-title">From App to Health Infrastructure</div>
                        <p class="hero-tagline">
                            Phase 4 transforms Elisence from a single application into a governance-grade,
                            audit-ready health intelligence infrastructure for ministries, hospitals and regulators.
                        </p>
                        <p class="hero-body">
                            It is the layer where **every number, model and comparison is traceable**.
                            WORM audit logs, FHIR interoperability, advanced provenance and AKAC privacy
                            controls ensure that real-world evidence is safe, verifiable and compatible
                            with national healthcare standards across the UK, EU, US and GCC regions.
                        </p>
                        <div class="hero-footnote">
                            <span>Stable · Auditable · Privacy-First · Comparative Intelligence</span>
                        </div>
                    </div>
                </div>
            </section>

            <!-- کارت‌های جزئیات (کامل، بدون خلاصه‌نویسی) -->
            <section class="card-grid">

                <!-- کارت ۱: Vision + Core Engine -->
                <article class="info-card">
                    <h2 class="info-title">1. Vision – Why Phase 4 Exists</h2>
                    <div class="info-body">
                        <p>
                            Phase 4 establishes the foundation where governments, clinicians and citizens
                            can trust Elisence’s conclusions at **national scale**. It guarantees that:
                        </p>
                        <ul>
                            <li>All real-world evidence (RWE) is traceable from input to output.</li>
                            <li>Every analytical result is backed by immutable logs and QA.</li>
                            <li>Privacy and clinical safety are enforced by design, not by policy only.</li>
                        </ul>
                        <p>
                            This is the layer that prepares Elisence for **formal evaluation** by ministries of health,
                            national health services and global partners.
                        </p>

                        <h3 class="info-subtitle">2. Core Engine – Four Technical Pillars</h3>
                        <p class="info-subtitle">
                            WORM Ledger · FHIR Interoperability · Provenance Engine · AKAC
                        </p>

                        <p class="highlight">2.1 WORM Ledger — Immutable Audit Trails</p>
                        <p>
                            A cryptographically enforced, append-only ledger that stores:
                        </p>
                        <ul>
                            <li>Dataset fingerprints and hashes.</li>
                            <li>Model version identifiers and configuration snapshots.</li>
                            <li>QA digests and full test outcomes.</li>
                            <li>Export hashes, signatures and delivery timestamps.</li>
                            <li>Archive and snapshot timestamps.</li>
                        </ul>
                        <p>
                            <strong>Why it matters:</strong> regulators and hospitals can reconstruct
                            exactly how a conclusion was produced. There are **no silent edits**, no hidden changes,
                            and no trust gaps.
                        </p>

                        <p class="highlight">2.2 FHIR Integration — Global Interoperability</p>
                        <p>
                            Phase 4 harmonises medication and usage data with global medical standards:
                        </p>
                        <ul>
                            <li>FHIR resources: <em>Medication</em>, <em>MedicationRequest</em>, <em>MedicationStatement</em>.</li>
                            <li>RxNorm / ATC codes for drug identification.</li>
                            <li>MedDRA for adverse event and side-effect coding.</li>
                            <li>SNOMED CT / ICD-10 for conditions and diagnoses.</li>
                        </ul>
                        <p>
                            <strong>Why it matters:</strong> ministries, hospitals and health systems can integrate Elisence
                            without rebuilding their infrastructure. FHIR makes Elisence **“plug-into-the-health-system ready.”**
                        </p>
                    </div>
                </article>

                <!-- کارت ۲: ادامه Core Engine (Provenance + AKAC) -->
                <article class="info-card">
                    <h2 class="info-title">2. Core Engine (continued) – Provenance & AKAC</h2>
                    <div class="info-body">
                        <p class="highlight">2.3 Provenance Engine — End-to-End Traceability</p>
                        <p>
                            Every analysis, chart, comparison or export carries embedded provenance metadata:
                        </p>
                        <ul>
                            <li>Data sources and ingestion paths.</li>
                            <li>Transformations, filters and quality checks applied.</li>
                            <li>Model parameters, training lineage and runtime versions.</li>
                            <li>Timestamps, environment and execution context.</li>
                            <li>Digital signatures, QA status and reviewer information.</li>
                            <li>AKAC privacy level and cohort size used.</li>
                        </ul>
                        <p>
                            This provides true real-world evidence transparency, aligned with
                            UK / EU / US / GCC expectations for medical data and pharmacovigilance.
                        </p>

                        <p class="highlight">2.4 AKAC — Adaptive Knowledge Access Control</p>
                        <p>
                            AKAC is a dynamic privacy supervisor that:
                        </p>
                        <ul>
                            <li>Adjusts anonymisation thresholds based on cohort size.</li>
                            <li>Applies k-anonymity and safe aggregation rules.</li>
                            <li>Blocks unsafe slices, drill-downs or high-risk combinations.</li>
                            <li>Ensures aggregate reports cannot deanonymise individuals.</li>
                        </ul>
                        <p>
                            <strong>Why it matters:</strong> citizens gain confidence that their identity is protected;
                            regulators gain formal proof of compliance; clinicians still receive **useful, safe insights**.
                        </p>
                    </div>
                </article>

                <!-- کارت ۳: Intelligence & Analytics -->
                <article class="info-card">
                    <h2 class="info-title">3. Intelligence & Analytics</h2>
                    <div class="info-body">
                        <p>
                            Phase 4 houses the analytical brain of Elisence, converting raw usage data into
                            trusted insight for **public health, clinical practice and national decision-making**.
                        </p>

                        <p class="highlight">3.1 Drug Effectiveness Intelligence</p>
                        <p>The engine computes, with QA and provenance on each metric:</p>
                        <ul>
                            <li>Mean effectiveness metrics and improvement scores.</li>
                            <li>Response rates across cohorts and sub-populations.</li>
                            <li>Δ-change metrics (before / after treatment windows).</li>
                            <li>Net Benefit Index (NBI) combining benefit and safety.</li>
                            <li>Cohort-specific performance curves over time.</li>
                        </ul>

                        <p class="highlight">3.2 Side-Effect Intelligence</p>
                        <p>
                            Integrated safety analytics using:
                        </p>
                        <ul>
                            <li>MedDRA-coded adverse events with severity grading.</li>
                            <li>Proportional Reporting Ratios (PRR) and ROR calculations.</li>
                            <li>Temporal patterns – onset, duration and recurrence.</li>
                            <li>Geo-demographic risk variations and clusters.</li>
                        </ul>
                        <p>
                            This produces contextualised safety profiles for public health and for
                            clinician governance boards.
                        </p>
                    </div>
                </article>

                <!-- کارت ۴: Comparative Engine + Global Medical Intelligence -->
                <article class="info-card">
                    <h2 class="info-title">3. Comparative & Global Medical Intelligence</h2>
                    <div class="info-body">
                        <p class="highlight">3.3 Comparative Intelligence Engine</p>
                        <p>
                            The flagship capability of Phase 4, enabling:
                        </p>
                        <ul>
                            <li>Drug-vs-drug comparisons across matched cohorts.</li>
                            <li>Cohort matching and propensity-score weighting.</li>
                            <li>Benefit–risk scoring, ranking and scenario exploration.</li>
                            <li>
                                Multilingual narrative generation (EN / FA / AR / TR / RO)
                                explaining results in plain language.
                            </li>
                        </ul>
                        <p>
                            <strong>Narrative example:</strong><br />
                            “Drug&nbsp;B showed substantially higher effectiveness and fewer severe adverse
                            events than Drug&nbsp;A in this cohort, based on anonymised real-world data.”
                        </p>
                        <p>
                            This allows clinicians and ministries to compare therapeutic options
                            **without guesswork or black-box behaviour**.
                        </p>

                        <p class="highlight">3.4 Global Medical-Intelligence Layer</p>
                        <p>
                            A unified intelligence fabric that powers:
                        </p>
                        <ul>
                            <li>National health and utilisation reports.</li>
                            <li>Population-level analytics and trend detection.</li>
                            <li>Ministry dashboards and oversight tools.</li>
                            <li>High-level, non-diagnostic risk–benefit summaries for citizens.</li>
                        </ul>
                        <p>
                            This layer turns Elisence from an app into a **real health-system intelligence backbone**.
                        </p>
                    </div>
                </article>

                <!-- کارت ۵: Safety & Governance -->
                <article class="info-card">
                    <h2 class="info-title">4. Safety, Governance & Compliance</h2>
                    <div class="info-body">
                        <p class="highlight">4.1 QA Gates – No Output Without Evidence</p>
                        <p>
                            No analytical output is released unless it passes a chain of QA gates:
                        </p>
                        <ul>
                            <li>Completeness and coverage checks.</li>
                            <li>Recency and freshness of data.</li>
                            <li>Duplicate and outlier detection.</li>
                            <li>Internal consistency and plausibility checks.</li>
                            <li>Cohort safety and minimum-size thresholds.</li>
                            <li>Privacy and AKAC compliance checks.</li>
                        </ul>
                        <p>
                            If any gate fails → the output is **blocked, flagged and not shown** to end users.
                        </p>

                        <p class="highlight">4.2 Governance of Effectiveness & Adverse Intelligence</p>
                        <ul>
                            <li>Transparent, documented statistical methodology.</li>
                            <li>Versioned models with full changelog and review trail.</li>
                            <li>Clear statement of assumptions and known limitations.</li>
                            <li>Clinical-grade metrics and validation procedures.</li>
                            <li>Multilingual narratives for global clinical and policy use.</li>
                        </ul>
                    </div>
                </article>

                <!-- کارت ۶: Compliance frameworks + Stakeholder impact & Scaling -->
                <article class="info-card">
                    <h2 class="info-title">5. Compliance, Impact & Scalability</h2>
                    <div class="info-body">
                        <p class="highlight">4.3 Trust Compliance Framework</p>
                        <p>
                            Phase 4 aligns with the operational expectations of:
                        </p>
                        <ul>
                            <li>GDPR and the UK Data Protection Act.</li>
                            <li>NHS DTAC principles for digital health.</li>
                            <li>EU MDR-aligned non-diagnostic AI behaviour.</li>
                            <li>HIPAA-style de-identification expectations.</li>
                            <li>GCC / Qatar / UAE PDPL-style privacy requirements.</li>
                            <li>ENCePP, STROBE and RECORD-PE for real-world evidence.</li>
                        </ul>
                        <p>
                            Outcome: Elisence becomes eligible for **formal evaluation** by healthcare authorities,
                            ethics boards and national partners.
                        </p>

                        <p class="highlight">5.1 Stakeholder Impact</p>
                        <p><strong>Governments & Ministries of Health</strong></p>
                        <ul>
                            <li>National-scale monitoring of drug safety and effectiveness.</li>
                            <li>Immutable WORM logs for compliance and investigations.</li>
                            <li>Real-world comparative intelligence for formulary and policy decisions.</li>
                            <li>Audit-ready provenance for every aggregate metric.</li>
                            <li>Privacy-by-design architecture backed by AKAC and anonymisation.</li>
                        </ul>

                        <p><strong>Hospitals, Clinics & Medical Networks</strong></p>
                        <ul>
                            <li>Evidence-backed medication comparisons at population and service level.</li>
                            <li>Safety signals and adverse-event intelligence for governance boards.</li>
                            <li>Transparent QA and methodology reports.</li>
                            <li>Multilingual clinical narratives for diverse populations.</li>
                            <li>Interoperability with existing EHR / FHIR systems.</li>
                        </ul>

                        <p><strong>Citizens & Families</strong></p>
                        <ul>
                            <li>Trust that identifiable data is never exposed in analytics.</li>
                            <li>Assurance that outputs are QA-checked and evidence-based.</li>
                            <li>Clear, human-friendly explanations of high-level patterns.</li>
                            <li>Future personalised coaching powered by aggregated RWE.</li>
                            <li>Strong privacy using AKAC, anonymisation and (later) differential privacy.</li>
                        </ul>

                        <p class="highlight">5.2 Scalability & Performance</p>
                        <ul>
                            <li>Pre-computed aggregates targeting &lt; 200&nbsp;ms API latency.</li>
                            <li>Optimised ETL and caching strategies for national workloads.</li>
                            <li>Archiving and snapshot systems for long-term reliability.</li>
                            <li>Partitioned analytics structures and safe cohorting.</li>
                            <li>WORM-integrated distributed ledger for durable audit history.</li>
                        </ul>

                        <p>
                            Phase 4 prepares Elisence for later expansions – diabetes intelligence (Phase&nbsp;9),
                            Women+ engines (Phase&nbsp;7), passports and access layers, public dashboards
                            and research portals – all resting on the same integrity and trust created here.
                        </p>

                        <p class="highlight">7. Final Statement</p>
                        <p>
                            Phase 4 is the moment Elisence becomes **infrastructure**, not just an app.
                            It provides the stability, transparency, governance and comparative intelligence
                            that governments, clinicians and citizens need in order to rely on its outputs.
                            All advanced capabilities in later phases are built on this foundation.
                        </p>
                    </div>
                </article>

            </section>

        </div>
    </div>

    <!-- ریشهٔ ویجت Elisa (مثل index و phase2) -->
    <div id="elisa-chat-root"></div>

</body>
</html>
